This synergy, as well as the potent inhibition of both IL-6 and CXCL8 by an NSKI, suggest that targeting a few select kinases may be a potential new mechanism for anti-inflammatory therapy in the context of Pa infections in CF and other patients. Here, IL6 is linked to cystic fibrosis.